Asia-Pacific journal of clinical oncology最新文献

{"title":"Systematic Literature Review on the Burden of Human Papillomavirus Infection and Related Diseases in India","authors":"De Partha,&nbsp;Rambhad Gautam S ,&nbsp;Wu Ying Hui,&nbsp;Sukarom Isaya","doi":"10.1111/ajco.14181","DOIUrl":"10.1111/ajco.14181","url":null,"abstract":"<p>Human papillomavirus (HPV)-related diseases pose public health concerns for both genders, yet their understanding remains limited in India. This review outlines HPV incidence and prevalence, genotype distribution, and attribution rates across different HPV-related disease types. A comprehensive literature search was performed to identify observational studies on individuals aged 15 years and older, and a total of 3702 publications were identified. A total of 139 studies were included in this review, involving 607,425 subjects aged 15.8–82.2 years, with a gender distribution of 38.13% males and 61.86% females. The prevalence of HPV infection in the anogenital area among healthy males and females was 41.07% and between 0.4% and 41.8%, respectively. Among individuals with HPV-related diseases, HPV infection prevalence was 26.1%–100% in unhealthy cervixes and cervical lesions, 3.1%–41% in anal lesions, 71.4% in vulva and vaginal lesions, and 0%–92.3% in head and neck cancer. The review highlights the variability in HPV prevalence across genders and age groups in India, likely due to population heterogeneity and testing differences. This study highlights the need for rigorous and uniform studies in India on the HPV disease burden and the importance of gathering evidence with a special focus on males.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 5","pages":"474-501"},"PeriodicalIF":1.6,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14181","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer Awareness and the Practice of Self Breast Examination Among Undergraduate Students in Karachi, Pakistan.","authors":"Mubashir Zafar, Tafazzul Hyder Zaidi, Nadira Hyder Zaidi, Amber Ilyas, Syeda Ruqaya Neha Majeed, Iqra Manzoor, Tooba Sajid, Saadia Akram, Kiran Mehtab, Rahat Naz, Ayesha Mubbashir","doi":"10.1111/ajco.14182","DOIUrl":"https://doi.org/10.1111/ajco.14182","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer remains one of the most prevalent malignancies affecting women worldwide, and breast self-examination (BSE) is acknowledged as a sensitive method for its early detection. This study aimed to assess the level of awareness regarding both breast cancer and BSE among undergraduate students in Karachi, Pakistan.</p><p><strong>Methodology: </strong>A cross-sectional survey was conducted at a public-sector university in Karachi. A total of 328 female students were selected using multistage stratified cluster sampling. The Chi-square test was employed to evaluate differences in awareness levels across various socio-demographic characteristics, with a p value of less than 0.05 considered statistically significant. All ethical guidelines were strictly adhered to throughout the study.</p><p><strong>Results: </strong>The mean age of the participants was 22 years. The study revealed that younger age groups (18-22 years), first-year students from various colleges, and students enrolled in business programs exhibited significantly lower levels of awareness regarding both breast cancer and BSE (p value <0.005). Overall, appropriate levels of awareness were reported by 45.1% of the participants for breast cancer and 47.3% for BSE.</p><p><strong>Conclusion: </strong>The findings indicate that the awareness levels regarding breast cancer and BSE are inadequate, particularly among first-year students and those pursuing business-related studies. These results underscore the need for targeted educational interventions to enhance awareness and promote the early detection and effective management of breast cancer through the practice of BSE.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Setting the Benchmark: Patterns of Care and Outcomes for Early-stage Non-small Cell Lung Cancer in Queensland, Australia, 2011-2017.","authors":"Bryan A Chan, Danny R Youlden, Tracey Guan, Margot Lehman, Morgan Windsor, Alison Bolton, Nathan Dunn, Danica Cossio, Shoni Philpot, Jasotha Sanmugarajah","doi":"10.1111/ajco.14177","DOIUrl":"https://doi.org/10.1111/ajco.14177","url":null,"abstract":"<p><strong>Aim: </strong>Treatment paradigms for early-stage non-small cell lung cancer (NSCLC) are evolving rapidly. Our aim was to document baseline patterns of care and outcomes at the population level immediately prior to the introduction of immunotherapy.</p><p><strong>Methods: </strong>Data were obtained from the Queensland Oncology Repository. The study cohort comprised Queensland residents diagnosed with a non-metastatic primary NSCLC between 2011 and 2017, with follow-up on treatment and mortality to December 31, 2022. Poisson regression was used to determine patient and clinical characteristics associated with receiving different treatment modalities within 1 year of diagnosis. Variations in 5-year observed survival were assessed using flexible parametric modelling.</p><p><strong>Results: </strong>A total of 4445 people were included, of whom 30% were treated with surgery only, 15% with surgery plus chemotherapy and/or radiotherapy and 44% with chemotherapy and/or radiotherapy only. The remaining 10% did not receive any recorded treatment. People in outer regional/remote areas had lower rates of radiotherapy (relative likelihood [RL] = 0.87, 95% confidence interval [CI] 0.78-0.97) and chemotherapy (RL = 0.89, 95% CI 0.81-0.98) than those in major cities, but there were no significant differences by First Nations status or socio-economic status. Five-year observed survival varied from 63% (95% CI 60%-65%) for stage I to 41% (38%-45%) for stage II and 20% (18%-22%) for stage III. The treatment modality significantly affected survival irrespective of stage at diagnosis (all p < 0.001).</p><p><strong>Conclusion: </strong>Monitoring treatment outcomes for early-stage NSCLC at the population level is crucial for optimizing patient care, resource allocation and informing consumer choice. Emerging approaches involving immunotherapy are expected to further improve outcomes.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic Lobular Breast Cancer: Outcomes of Patients Treated at a Single Tertiary Institution.","authors":"Ek Leone Oh, Elizabeth Steinepreis, Chia Len, Hilary Martin","doi":"10.1111/ajco.14175","DOIUrl":"https://doi.org/10.1111/ajco.14175","url":null,"abstract":"<p><strong>Background: </strong>Management for lobular breast cancer is generally extrapolated from trials comprised predominantly of ductal breast cancer patients. However, lobular cancers are biologically distinct with associated treatment implications, but despite this, prospective trial data focusing on lobular cancers is lacking.</p><p><strong>Methods: </strong>We conducted a retrospective review of patients diagnosed with metastatic lobular breast cancer at our cancer service. We collected data on clinical characteristics and analysed treatment outcomes following various lines of systemic therapies.</p><p><strong>Results: </strong>Between January 2017 and April 2023, 21 patients with metastatic lobular breast cancer were identified. As expected, most (76.2%) patients had a hormone-receptor-positive HER2-negative (HR+HER2-) disease. The mean age at diagnosis of metastatic disease was 60.61 years, and the mean time to progression from early to metastatic disease was 8.45 years. Responses to systemic treatments given for metastatic disease varied significantly. For patients with HR+HER2- disease, the highest clinical benefit rate was observed with capecitabine, followed by a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor.</p><p><strong>Conclusion: </strong>This study aligns with existing literature in terms of the clinical characteristics of early lobular breast cancers. For metastatic disease, HR+HER2- lobular breast cancer treated with CDK4/6 inhibitors and non-steroidal aromatase inhibitors had a similar progression-free survival compared to the registration trial data supporting its use for lobular cancer. There were also some responses to chemotherapy, with all patients who received capecitabine obtaining clinical benefit. Patients with HER2+ disease had excellent outcomes, while outcomes were poor for triple-negative lobular breast cancer, though the small number of patients in our study limits interpretation.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic Breast Cancer Prevalence in New South Wales, Australia, in 2016: A Health Record Linkage Study","authors":"Andrea L. Smith,&nbsp;Xue Qin Yu,&nbsp;Dianne L. O'Connell,&nbsp;Nehmat Houssami,&nbsp;Belinda E. Kiely,&nbsp;Anne E. Cust,&nbsp;David P. Smith,&nbsp;Michael David,&nbsp;Sarah J. Lord","doi":"10.1111/ajco.14176","DOIUrl":"10.1111/ajco.14176","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To estimate the number of females living with metastatic breast cancer (MBC) in New South Wales (NSW), Australia, in 2016 using linked health records.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The primary study dataset (cohort 1) included females in the NSW Cancer Registry (NSWCR) with breast cancer diagnosed during 2001–2002 and 2006–2007 linked with administrative hospital records, medicine dispensing, radiation services, and death records. From this dataset we counted the number with a record of de novo MBC or recurrent MBC (following stage I–III cancer) alive at the end of each year (2001–2015). The second dataset (cohort 2) included females with breast cancer diagnosed 2003–2005 and 2008–2015 without linked records. We imputed MBC prevalence for cohort 2 by calculating MBC prevalence proportions at the end of each year in cohort 1 and applying these proportions to NSWCR incidence counts in cohort 2.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Cohort 1 comprised 16,521 females with breast cancer, of whom 4364 had MBC recorded (976 de novo; 3388 recurrent). A total of 1245 individuals with MBC recorded were alive on January 1, 2016 (270 de novo, 21.7%; 975 recurrent, 78.3%). When extrapolated to all females diagnosed with breast cancer in 2001–2015 in NSW, 5009 individuals were estimated to be living with MBC on January 1, 2016 (1609 de novo, 32.1%; 3400 recurrent, 67.9%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study estimates that a large number of individuals are living with MBC and demonstrates the importance of identifying individuals with recurrent MBC, in addition to de novo MBC, to inform funding and delivery of appropriate clinical and supportive care services.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 4","pages":"407-414"},"PeriodicalIF":1.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14176","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Nationwide Survey on Knowledge, Attitudes, and Practices of Filipino Oncologists and Oncology-Related Professionals on Shared Decision Making.","authors":"Francis Matthew Pleta, Reigen Placido, Delfin Yñigo Pilapil, Ma Dianne Parado, Amanda Pauline Paris, Neil Joshua Patiag, Alfonzo Martin Pedro, Julia Audrey Peralta, Regis Patrick Pilar, Herdee Gloriane Luna, Warren Bacorro","doi":"10.1111/ajco.14178","DOIUrl":"https://doi.org/10.1111/ajco.14178","url":null,"abstract":"<p><strong>Aim: </strong>To explore the knowledge, attitudes, and practices of Filipino oncologists and oncology-related professionals on shared decision making (SDM), evaluate their familiarity with and use of evidence-based medicine (EBM) and clinical practice guidelines (CPG), and identify barriers and facilitators to SDM.</p><p><strong>Methods: </strong>A cross-sectional, nationwide online survey was conducted from April 1 to May 15, 2024, using voluntary response sampling.</p><p><strong>Results: </strong>87 respondents participated. Most practice in the National Capital Region (NCR) (n = 48, 55%), Luzon (outside NCR) (n = 22, 25%), Mindanao (n = 11, 13%), and Visayas (n = 8, 9%); 56 (64%) practice in both government and private centers. Most lacked a full conceptual understanding of SDM. Almost all had a positive attitude toward its implementation. 62 (71%) indicated that they share responsibility with their patients for making decisions. The top reason for not applying SDM in appropriate situations was patient deference to the clinician's decision (n = 37, 43%). Choosing among treatment options with equivalent effectiveness but different toxicity profiles (n = 86, 99%) was the most reported situation deemed appropriate for SDM. Key barriers to SDM implementation were patient-related factors, family dynamics, health financing, and time constraints. Several expressed the need for adequate time and effective communication to facilitate SDM.</p><p><strong>Conclusion: </strong>Most surveyed Filipino oncologists and oncology-related professionals reported applying SDM and had a positive attitude toward it. However, a fuller conceptual understanding of the process is lacking. Patient-, family-, and health financing-related barriers were identified. Enhancing SDM education among oncologists may improve the clinical application, and exploring the perspectives of other stakeholders may enhance its institutionalization.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Change in the Neutrophil-Lymphocyte Ratio and Recurrence in Operated Bladder Cancer.","authors":"Amnuay Kleebayoon, Viroj Wiwanitkit","doi":"10.1111/ajco.14183","DOIUrl":"https://doi.org/10.1111/ajco.14183","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic [68Ga]Ga-PSMA-11 PET Biomarkers for [177Lu]Lu-PSMA Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer (Asian Population Study)","authors":"Nicola Xin Yi Koh,&nbsp;Wei Ming Chua,&nbsp;Winnie Wing-Chuen Lam,&nbsp;Aaron Kian-Ti Tong,&nbsp;Ravindran Kanesvaran,&nbsp;Alvin Seng Cheong Wong,&nbsp;Kenneth Chen,&nbsp;Sue Ping Thang","doi":"10.1111/ajco.14174","DOIUrl":"10.1111/ajco.14174","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Gallium-68 (⁶⁸Ga) prostate-specific membrane antigen (PSMA) ([⁶⁸Ga]Ga-PSMA-11) directed PET/CT reflects PSMA expression at metastatic sites and can hence be a surrogate of lutetium-177 (¹⁷⁷Lu) PSMA ([¹⁷⁷Lu]Lu-PSMA) radiation delivery. This retrospective analysis aims to explore the association between quantitative baseline [⁶⁸Ga]Ga-PSMA-11 PET imaging biomarkers and treatment outcomes in our Asian cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We included patients with progressive metastatic castrate-resistant prostate cancer (mCRPC) who received [¹⁷⁷Lu]Lu-PSMA radioligand therapy at our institution. The association between baseline [⁶⁸Ga]Ga-PSMA-11 PET parameters (SUVmax, SUVmean, total tumor volume [PSMA-TV], total lesion uptake [PSMA-TLU = PSMA-TV × SUVmean], and total lesion quotient [PSMA-TLQ = PSMA-TV / SUVmean]) and overall survival (OS), prostate specific antigen (PSA) progression free survival (PFS), PSA response, and toxicity were analyzed using univariate analysis. Optimal cut-points were also explored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Between May 9, 2018 and October 7, 2024, 71 of 84 screened patients were eligible. The median whole-body SUVmean in our cohort was 8.04. Higher PSMA-TLQ and PSMA-TV (per 10-unit increment) were associated with shorter OS (HR 1.005; HR 1.005) and shorter PSA PFS (HR 1.005; HR 1.004). A higher PSMA-TLQ was also associated with poorer odds of PSA response (OR 0.994). Conversely, higher SUVmean was associated with longer PSA PFS (HR 0.911) and improved odds of PSA response (OR 1.34). Higher PSMA-TV (per 10-unit increment) and PSMA-TLU (per 100-unit increment) were associated with increased hematological toxicity (OR 1.008; OR 1.012).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>PSMA-TLQ and PSMA-TV were negative prognostic markers and SUVmean was a positive prognostic marker among Asian patients with mCRPC who received [¹⁷⁷Lu]Lu-PSMA radioligand therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 4","pages":"399-406"},"PeriodicalIF":1.4,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding the Role of CDCA Genes in Breast Cancer Progression: Insights From in Silico and Functional Assay","authors":"Yongsheng Zhao,&nbsp;Xiaocha Ma,&nbsp;Jun Zhou","doi":"10.1111/ajco.14173","DOIUrl":"10.1111/ajco.14173","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The cell division cycle-associated (CDCA) genes regulate key cellular processes like cell cycle progression and division. This study evaluates the diagnostic and clinical relevance of CDCA genes in breast cancer.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methodology&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Breast cancer and normal breast cell lines were cultured and analyzed for CDCA gene expression using RT-qPCR and further validated using public databases. Functional assays, including cell proliferation, colony formation, and wound healing, were performed following siRNA-mediated knockdown of CDCA2 and CDCA3. Mutational, CNV, methylation, and survival analyses, along with miRNA regulation and PPI network construction, were conducted to explore the role of CDCA genes in breast cancer progression.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Our findings revealed significant upregulation of CDCA genes in breast cancer cell lines compared to normal controls, with all these genes exhibiting the highest diagnostic potential based on AUC values in ROC analysis. Pathological stage analysis indicated that CDCA5 and CDCA7 expression significantly varied across different breast cancer stages. Mutational analysis showed that CDCA2 had the highest mutation rate, with missense mutations being the most common. CNV analysis revealed amplification events in several CDCA genes, particularly CDCA2, CDCA3, CDCA4, and CDCA7. Promoter methylation analysis revealed significant hypomethylation in the CDCA genes in breast cancer, which correlated negatively with their expression. Survival analysis demonstrated that high expression of CDCA2, CDCA3, CDCA4, CDCA5, CDCA7, and CDCA8 was associated with worse overall survival, highlighting their prognostic significance. Furthermore, immune infiltration analysis revealed significant correlations between CDCA gene expression and immune cell types, suggesting a role in immune modulation. miRNA analysis identified specific miRNAs targeting CDCA genes, with several showing potential as diagnostic biomarkers. Lastly, the knockdown of CDCA2 and CDCA3 in breast cancer cells significantly reduced cell proliferation, colony formation, and migration, indicating their critical roles in tumor growth and metastasis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study highlights CDCA genes as promising diagnostic and prognostic biomarkers in breast cancer. Their upregulation correlates with poor survival, and the knockdown of CDCA2 and CDCA3 impairs tumor growth, emphasizing their potential as therapeutic targets. These findings suggest","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 5","pages":"566-577"},"PeriodicalIF":1.6,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14173","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulation of the MAPK/ERK Pathway by miRNA-27b in Gastric Cancer: Diagnostic Implications and Therapeutic Potential of Aloin.","authors":"Yang Dehuo, Wang Ying, Cao Lin","doi":"10.1111/ajco.14171","DOIUrl":"https://doi.org/10.1111/ajco.14171","url":null,"abstract":"<p><strong>Background: </strong>Globally, gastric cancer (GC) ranks as the fourth most deadly and fifth most prevalent kind of cancer. Appropriate treatment methods, precise etiology, and molecular processes of GC are still unclear.</p><p><strong>Methods: </strong>In silico and quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR)-based expression of miRNA-27b was quantified in GC cell lines (AGS, MKN-28, MKN-45, NCI-N87, SNU-1), and ROC curve analysis was done to evaluate their diagnostic efficiency. In silico target prediction through miRDB and TargetScan followed by in vitro validation was done using luciferase assays. Expression analysis of MAPK/ERK target genes including GRB2, SOS1, KRAS, BRAF, MAP2K1, and MAPK1 was done using qRT-PCR and Western blot analysis, followed by ROC curve analysis to evaluate their diagnostic efficiency. GC cell lines were treated with Aloin (ALO), followed by cell viability, wound healing, and apoptosis assays. Furthermore, the expression of MAPK/ERK pathway genes in GC cell lines was evaluated by qRT-PCR following ALO treatment.</p><p><strong>Results: </strong>The in silico analysis identified specific binding sites for miRNA-27b within the 3'UTRs of key components in the MAPK/ERK signaling pathway, including GRB2, SOS1, KRAS, BRAF, MAP2K1, and MAPK1. Luciferase reporter assays confirmed the direct interaction of miRNA-27b with these target genes, showing significantly reduced luciferase activity in cells transfected with wild-type 3'UTRs compared to controls. Expression analysis revealed that miRNA-27b was significantly downregulated in GC patients and cell lines when compared to normal controls. The downregulation of miRNA-27b was further validated through qRT-PCR in a variety of GC cell lines. ROC curve analysis demonstrated an AUC of 100 for miRNA-27b, suggesting its strong potential as a diagnostic biomarker for GC. In contrast, the expression of MAPK/ERK pathway genes was significantly upregulated in GC cell lines, with ROC analysis revealing high diagnostic accuracy for several genes, including GRB2, SOS1, and KRAS. Protein expression analysis via Western blot confirmed the upregulation of these pathway components in GC cells. Further investigation into the effects of ALO treatment showed a dose-dependent reduction in cell viability, migration, and colony formation in GC cell lines. ALO treatment also induced apoptosis, as evidenced by the upregulation of apoptotic markers and the downregulation of the anti-apoptotic molecule Bcl-2.</p><p><strong>Conclusion: </strong>MiRNA-27b and MAPK/ERK pathway genes (GRB2, SOS1, KRAS, BRAF, MAP2K1, and MAPK1) could serve as efficient diagnostic, prognostic, and therapeutic targets for GC patients. Furthermore, this study's findings shed light on ALO's anti-tumor capabilities by demonstrating that it inhibits GC cell migration and proliferation while restoring the expression status of MAPK/ERK pathway genes.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}